- Home
- MIY vs EYPT Comparison
MIY vs EYPT Comparison
Compare MIY & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MIY | EYPT |
|---|---|---|
| Founded | N/A | 1987 |
| Country | United States | United States |
| Employees | N/A | 214 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 334.3M | 273.3M |
| IPO Year | 1994 | 2005 |
Fundamental Metrics
Financial Performance| Metric | MIY | EYPT |
|---|---|---|
| Price | $11.27 | $3.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $25.91 |
| AVG Volume (30 Days) | 85.3K | ★ 3.2M |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $943.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.01 | $3.05 |
| 52 Week High | $12.90 | $19.11 |
Technical Indicators
Market Signals| Indicator | MIY | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 32.77 | 34.18 |
| Support Level | $11.30 | N/A |
| Resistance Level | $12.44 | $14.72 |
| Average True Range (ATR) | 0.24 | 0.26 |
| MACD | -0.04 | 0.18 |
| Stochastic Oscillator | 26.14 | 31.33 |
Price Performance
Historical ComparisonAbout MIY Blackrock MuniYield Michigan Quality Fund Inc.
Blackrock Muniyield Michigan Quality Fund Inc is a closed end fund. Its investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.